文献速递新发突发、热带与寄生虫病

单剂伯氨喹在无疟疾的马里G6PD缺乏及G6PD正常男性中的安全性:一项开放标签、1期、剂量调整试验

Safety of Single-Dose Primaquine in G6PD-Deficient and G6PD-Normal Males in Mali Without Malaria: An Open-Label, Phase 1, Dose-Adjustment Trial.
PubMed 文献 · J Infect Dis · 2018-01-01

在马里开展开放标签、非随机、剂量调整的1期试验,评估单剂伯氨喹在G6PD缺乏成年男性及11-17岁、5-10岁G6PD缺乏男孩(含G6PD正常对照组)中的安全性。主要结局为治疗后10天内血红蛋白浓度最大个体内下降百分比。结果显示0.40-0.50 mg/kg单剂伯氨喹耐受良好,无溶血症状证据,研究期间最低血红蛋白为92 g/L。

要点

  • G6PD缺乏成年男性接受0.40、0.45或0.50 mg/kg单剂伯氨喹,G6PD缺乏男孩接受0.40 mg/kg。
  • 研究期间最低血红蛋白浓度为92 g/L,未观察到有症状的溶血证据。
  • 研究者认为与研究药物相关的不良事件(n=4)均为轻度。

核心结论

  • 0.40至0.50 mg/kg的单剂伯氨喹在马里G6PD缺乏男性中耐受良好。

研究设计与样本

  • 开放标签、非随机、剂量调整的1期试验,纳入G6PD缺乏成年男性,随后评估G6PD缺乏11-17岁男孩和5-10岁男孩(含G6PD正常对照组)。
  • 共51名参与者纳入分析。
  • 主要结局为治疗后10天内血红蛋白浓度最大个体内下降百分比。

主要发现

  • G6PD缺乏成年男性接受0.50 mg/kg单剂伯氨喹后,第0天至第10天血红蛋白平均最大个体内变化为-9.7%(95%CI,-13.5%至-5.90%)。
  • G6PD缺乏11-17岁男孩接受0.40 mg/kg单剂伯氨喹后,第0天至第10天血红蛋白平均最大个体内变化为-11.5%(95%CI,-16.1%至-6.96%)。
  • G6PD缺乏5-10岁男孩接受0.40 mg/kg单剂伯氨喹后,第0天至第10天血红蛋白平均最大个体内变化为-9.61%(95%CI,-7.59%至-13.9%)。
  • 研究期间任何时间点的最低血红蛋白浓度为92 g/L。
  • 未观察到有症状的溶血证据,研究者认为与研究药物相关的不良事件(n=4)均为轻度。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The World Health Organization recommendation on the use of a single low dose of primaquine (SLD-PQ) to reduce Plasmodium falciparum malaria transmission requires more safety data. METHODS: We conducted an open-label, nonrandomized, dose-adjustment trial of the safety of 3 single doses of primaquine in glucose-6-phosphate dehydrogenase (G6PD)-deficient adult males in Mali, followed by an assessment of safety in G6PD-deficient boys aged 11-17 years and those aged 5-10 years, including G6PD-normal control groups. The primary outcome was the greatest within-person percentage drop in hemoglobin concentration within 10 days after treatment. RESULTS: Fifty-one participants were included in analysis. G6PD-deficient adult males received 0.40, 0.45, or 0.50 mg/kg of SLD-PQ. G6PD-deficient boys received 0.40 mg/kg of SLD-PQ. There was no evidence of symptomatic hemolysis, and adverse events considered related to study drug (n = 4) were mild. The mean largest within-person percentage change in hemoglobin level between days 0 and 10 was -9.7% (95% confidence interval [CI], -13.5% to -5.90%) in G6PD-deficient adults receiving 0.50 mg/kg of SLD-PQ, -11.5% (95% CI, -16.1% to -6.96%) in G6PD-deficient boys aged 11-17 years, and -9.61% (95% CI, -7.59% to -13.9%) in G6PD-deficient boys aged 5-10 years. The lowest hemoglobin concentration at any point during the study was 92 g/L. CONCLUSION: SLD-PQ doses between 0.40 and 0.50 mg/kg were well tolerated in G6PD-deficient males in Mali. CLINICAL TRIALS REGISTRATION: NCT02535767.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Chen I, Diawara H, Mahamar A, et al. Safety of Single-Dose Primaquine in G6PD-Deficient and G6PD-Normal Males in Mali Without Malaria: An Open-Label, Phase 1, Dose-Adjustment Trial. J Infect Dis. 2018. PMID: 29342267. doi:10.1093/infdis/jiy014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。